Mycophenolatemofetil Sandoz (Mycophenolate Mofetil)

Mycophenolate Mofetil is used in conditions where selective suppression of the immune response is required.

• Organ transplant rejection: helps prevent graft rejection and supports long‑term graft survival.
• Lupus nephritis: reduces renal inflammation and slows disease progression in systemic lupus erythematosus affecting the kidneys.
• Other autoimmune disorders: mitigates disease activity in conditions such as vasculitis or dermatomyositis where T‑cell mediated damage is prominent.

• Mycophenolate Mofetil is a pro‑drug that is converted to mycophenolic acid, which selectively inhibits inosine monophosphate dehydrogenase (IMPDH). This enzyme blockade reduces guanine nucleotide synthesis, limiting the proliferation of activated T and B lymphocytes and thereby dampening the adaptive immune response.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects

• Gastrointestinal upset: nausea, vomiting, diarrhea, or abdominal pain.
• Hematologic changes: anemia, leukopenia, or thrombocytopenia.
• Infections: increased susceptibility to bacterial, viral, or fungal infections.
• Headache or dizziness.

Serious or Rare Side Effects

• Severe infections such as opportunistic or reactivating infections.
• Progressive multifocal leukoencephalopathy (PML).
• Malignancies, particularly lymphoproliferative disorders.
• Hepatotoxicity: elevated liver enzymes or hepatitis.

Before initiating therapy, clinicians should assess patient‑specific risk factors and monitor relevant parameters.

• Baseline labs: obtain complete blood count and liver function tests.
• Infection risk: screen for latent viral infections (e.g., CMV, EBV) and vaccinate when appropriate.
• Renal function: adjust monitoring in patients with impaired kidney function.
• Pregnancy and lactation: avoid use unless benefits clearly outweigh risks; discuss contraception.
• Drug interactions: review concomitant medications for potential interactions.
• Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Mycophenolate Mofetil can alter the effectiveness or toxicity of several co‑administered agents.

Major Interactions (Avoid)

• Antimetabolites such as azathioprine: additive bone‑marrow suppression.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce mycophenolic acid exposure.

Moderate Interactions (Monitor Closely)

• Antacids containing aluminum or magnesium: may decrease absorption; separate dosing by at least 2 hours.
• ACE inhibitors or ARBs: monitor renal function and potassium levels.
• Vaccines: live attenuated vaccines should be avoided during therapy.